|Bid||0.00 x 0|
|Ask||0.00 x 0|
|Day's Range||561.05 - 593.70|
|52 Week Range||480.20 - 621.25|
|PE Ratio (TTM)||47.24|
|Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
To access the newsletter, click on the link: http://share.thomsonreuters.com/assets/newsletters/Indiamorning/MNC_IN_08142017.pdf If you would like to receive this newsletter via email, please register ...
Indian drugmaker Cipla Ltd's third-quarter profit beat estimates due to higher sales in the United States, and the company said it was looking for licensing deals and acquisitions to build its speciality medicines pipeline in that market. The country's fifth-largest drugmaker by sales reported a roughly 21 percent rise in revenue from North America for the October-December period. Cipla bought two U.S. generic drug producers, Invagen and Exelan, for about $550 million last year in its first big move to expand in a market where most of its local peers already have a large presence.
Several companies, including Indian units of Abbott Laboratories and Pfizer Inc , and domestic firms like Cipla Ltd and Macleods Pharmaceuticals, went to the Delhi High Court to try to get the ban lifted. On Monday, judge Rajiv Sahai Endlaw moved the hearing into his chamber from a courtroom packed with lawyers and company executives. Archana Sachdeva, a lawyer representing Cipla among other firms, said he had ordered the next hearing on March 28.